Opus Genetics announced positive 3- and 6-month results from the low-dose cohort 1 of BIRD-1, the ongoing phase 1/2 ...

A JAMA Ophthalmology Clinical Trial of the Year enrolled 1421 eyes across 28 sites, with NEI-funded follow-up extending the ...

Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.

Care has launched the IC1000, a handheld rebound tonometer the company describes as the next step in its guided approach to intraocular pressure (IOP) measurement. The device combines the company's ...

Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye ...

The FDA accepted Nanoscope's BLA for MOGENRY (sonpiretigene isteparvovec, MC-010), a gene therapy for retinitis pigmentosa with severe vision loss, supported by RESTORE trial data showing sustained ...

Extended-release drug delivery is reshaping the treatment landscape for retinal vascular disease, offering a potential answer to the persistent gap between the efficacy of anti-VEGF therapy in ...

University of Iowa researchers received federal funding from the NIH to advance an antioxidant -based technology that may ...

InVision Eye Care is using a virtual reality-based patient education tool to show patients with cataracts what their vision ...

Any patient presenting with new-onset NAION should be asked about PDE-5 inhibitor use—including over-the-counter or online purchases that may not appear on a medication list—and, increasingly, about ...

Giant cell arteritis, long known by its more familiar name, temporal arteritis, is the most common vasculitis in adults over ...

John W. Kitchens, MD, discusses patient selection for geographic atrophy treatment, counseling approaches, and emerging ...